Analyst Reco. Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
469.34 ^USD	-1.84%		+2.77%	+3.52%

03-11	Vertex Pharmaceuticals Incorporated Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:30 AM
03-10	US Equity Markets Mixed Amid Volatility, Crude Oil Price Rebound	MT

Analyst Reco.

03-10	Truist Securities Adjusts Price Target on Vertex Pharmaceuticals to $525 From $490, Maintains Buy Rating	MT
03-10	HC Wainwright Adjusts Vertex Pharmaceuticals PT to $641 From $591, Maintains Buy Rating	MT
03-10	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $641 From $625, Maintains Buy Rating	MT
03-10	Citigroup Adjusts Price Target on Vertex Pharmaceuticals to $585 From $575, Maintains Buy Rating	MT
03-10	Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $596 From $570, Maintains Overweight Rating	MT
03-02	BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $600 From $530, Maintains Outperform Rating	MT
02-26	Daiwa Securities Adjusts Vertex Pharmaceuticals PT to $561 From $500, Maintains Buy Rating	MT
02-17	HC Wainwright Adjusts Price Target on Vertex Pharmaceuticals to $591 From $518, Maintains Buy Rating	MT
02-17	Rothschild & Co Redburn Adjusts Price Target on Vertex Pharmaceuticals to $570 From $545, Maintains Buy Rating	MT
02-13	Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says	MT
02-13	Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says	MT
02-13	Canaccord Genuity Adjusts Vertex Pharmaceuticals Price Target to $441 From $411, Maintains Hold Rating	MT
02-13	Barclays Adjusts Price Target on Vertex Pharmaceuticals to $607 From $606, Maintains Overweight Rating	MT
02-13	HC Wainwright Adjusts Vertex Pharmaceuticals PT to $518 From $478, Maintains Buy Rating	MT
02-13	RBC Trims Price Target on Vertex Pharmaceuticals to $541 From $546, Keeps Outperform Rating	MT
02-13	Oppenheimer Upgrades Vertex Pharmaceuticals to Outperform From Market Perform	MT
02-13	Bernstein Adjusts Vertex Pharmaceuticals Price Target to $577 From $572, Maintains Outperform Rating	MT
02-13	Cantor Fitzgerald Adjusts Vertex Pharmaceuticals Price Target to $590 From $485, Maintains Overweight Rating	MT
02-13	Scotiabank Adjusts Vertex Pharmaceuticals PT to $558 From $495, Maintains Sector Outperform Rating	MT
02-13	Stifel Nicolaus Adjusts Vertex Pharmaceuticals PT to $466 From $445, Maintains Hold Rating	MT
02-10	Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says	MT
01-26	UBS Adjusts Price Target on Vertex Pharmaceuticals to $545 From $535, Maintains Buy Rating	MT
01-23	Evercore ISI Adjusts Price Target on Vertex Pharmaceuticals to $530 From $475, Maintains Outperform Rating	MT
01-22	Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says	MT
01-22	RBC Upgrades Vertex Pharmaceuticals to Outperform From Sector Perform, Raises Price Target to $546 From $455	MT